Prusogliptin

Prusogliptin
Clinical data
Other names	DBPR108
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S,4S)-4-Fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile;
CAS Number	1186426-66-3 ;
PubChem CID	44201003 ;
ChemSpider	24662486 ;
UNII	E329HG23ZT ;
ChEMBL	ChEMBL1082462 ;
Chemical and physical data
Formula	C16H25FN4O2
Molar mass	324.400 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F;
	InChI InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1; Key:VQKSCYBKUIDZEI-STQMWFEESA-N;

Last updated July 16, 2025

Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.^[1]^[2]^[3]

References

↑ Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao; Yuan, Jing; Xiao, Xinhua (November 2022). "Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism. 24 (11): 2232–2240. doi:10.1111/dom.14810. PMC 9796963 . PMID 35791646.
↑ Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui; Song, Jen-Shin; Hsu, Tsu; Jiaang, Weir-Torn; Chao, Yu-Sheng; Chen, Chiung-Tong (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences. 278 119574. doi:10.1016/j.lfs.2021.119574. PMID 33961850. S2CID 233999305.
↑ Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming; Li, Feng; Zhang, Xiaomei; Li, Xuefeng; Peng, Yongde; Deng, Hongyan; Xu, Xiangjin; Zhou, Ligang; Huang, Yanli; Cao, Mengya; Xia, Xuefang; Shi, Mingbiao; Dou, Jing; Yuan, Jing (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion. 36 (7): 1107–1115. doi:10.1080/03007995.2020.1761311. PMID 32338063. S2CID 216555956.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao; Yuan, Jing; Xiao, Xinhua (November 2022). "Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism. 24 (11): 2232–2240. doi:10.1111/dom.14810. PMC 9796963 . PMID 35791646.

[2] Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui; Song, Jen-Shin; Hsu, Tsu; Jiaang, Weir-Torn; Chao, Yu-Sheng; Chen, Chiung-Tong (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences. 278 119574. doi:10.1016/j.lfs.2021.119574. PMID 33961850. S2CID 233999305.

[3] Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming; Li, Feng; Zhang, Xiaomei; Li, Xuefeng; Peng, Yongde; Deng, Hongyan; Xu, Xiangjin; Zhou, Ligang; Huang, Yanli; Cao, Mengya; Xia, Xuefang; Shi, Mingbiao; Dou, Jing; Yuan, Jing (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion. 36 (7): 1107–1115. doi:10.1080/03007995.2020.1761311. PMID 32338063. S2CID 216555956.

[1]

[2]

[3]